^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: MK-2870, SKB 264, SKB264, sac-TMT, SKB-264, MK2870, MK 2870
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) (TroFuse-004) (NCT06074588)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/12/2023
    Primary completion :
    05/10/2027
    Completion :
    03/11/2030
    EGFR • BRAF
    |
    EGFR mutation • EGFR T790M
    |
    docetaxel • pemetrexed • Jiataile (sacituzumab tirumotecan)
    A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (SKB264-II-04) (NCT05816252)
    Phase 2
    Klus Pharma Inc.
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    04/19/2023
    Primary completion :
    12/01/2025
    Completion :
    10/30/2026
    EGFR • ALK
    |
    EGFR mutation • ALK fusion
    |
    Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • Jiataile (sacituzumab tirumotecan)
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499)
    Phase 1/2
    Klus Pharma Inc.
    Recruiting
    Last update posted :
    06/24/2024
    Initiation :
    02/28/2020
    Primary completion :
    08/01/2025
    Completion :
    07/16/2026
    EGFR • HER-2 • MSI • BRCA • TACSTD2
    |
    MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation
    |
    Jiataile (sacituzumab tirumotecan)
    Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) (NCT06049212)
    Phase 1
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    10/26/2023
    Primary completion :
    06/06/2025
    Completion :
    06/06/2025
    EGFR • PD-L1 • ROS1
    |
    Keytruda (pembrolizumab) • carboplatin • Jiataile (sacituzumab tirumotecan)
    SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (NCT05351788)
    Phase 2
    Sichuan Kelun Pharmaceutical Research Institute...
    Recruiting
    Last update posted :
    12/14/2023
    Initiation :
    05/20/2022
    Primary completion :
    08/01/2024
    Completion :
    04/01/2026
    ALK
    |
    EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
    |
    cisplatin • carboplatin • Jiataile (sacituzumab tirumotecan) • tagitanlimab (HBM9167)
    SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors (NCT05631262)
    Phase 2
    Sichuan Kelun Pharmaceutical Research Institute...
    Recruiting
    Last update posted :
    10/24/2023
    Initiation :
    11/30/2022
    Primary completion :
    10/30/2024
    Completion :
    10/30/2025
    ALK
    |
    EGFR mutation • EGFR wild-type • ALK fusion
    |
    docetaxel • Jiataile (sacituzumab tirumotecan)
    SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer (NCT05445908)
    Phase 2
    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    10/20/2023
    Initiation :
    08/17/2022
    Primary completion :
    04/01/2025
    Completion :
    07/01/2025
    HER-2
    |
    HER-2 negative
    |
    Jiataile (sacituzumab tirumotecan) • tagitanlimab (HBM9167)
    SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (NCT05347134)
    Phase 3
    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Active, not recruiting
    Last update posted :
    10/20/2023
    Initiation :
    06/10/2022
    Primary completion :
    10/31/2023
    Completion :
    12/31/2024
    HER-2 • PGR • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (SKB264-Ⅲ-10) (NCT06081959)
    Phase 3
    Sichuan Kelun Pharmaceutical Research Institute...
    Not yet recruiting
    Last update posted :
    10/13/2023
    Initiation :
    11/30/2023
    Primary completion :
    03/31/2026
    Completion :
    12/31/2027
    HER-2
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)